当前位置:科学网首页 > 小柯机器人 >详情
Ad26疫苗可在仓鼠中预防重症SARS-CoV-2
作者:小柯机器人 发布时间:2020/9/4 15:09:16

美国哈佛医学院Dan H. Barouch小组发现,Ad26疫苗可在仓鼠中预防重症SARS-CoV-2。这一研究成果于2020年9月3日在线发表在《自然—医学》上。

研究人员发现,仓鼠大剂量鼻内SARS-CoV-2感染会导致严重的临床疾病,包括组织中病毒复制水平高、广泛的肺炎、体重减轻和部分动物死亡。表达稳定型SARS-CoV-2突刺蛋白的腺病毒血清型26载体疫苗的单次免疫可引起结合和中和抗体反应,并防止SARS-CoV-2引起的体重减轻、肺炎和死亡。这些数据证明了针对SARS-CoV-2临床疾病的疫苗保护作用。该模型可用于SARS-CoV-2疫苗的临床前研究、治疗方法和发病机理。
 
据介绍,2019人类冠状病毒病(COVID-19)通常是临床上轻度的疾病,但有些人会发展为严重的肺炎、呼吸衰竭和死亡。关于仓鼠和非人类灵长类动物中的SARS-CoV-2感染的研究通常报告了轻度的临床疾病,而临床前SARS-CoV-2疫苗研究表明病毒的复制能够在非人类灵长类动物的上呼吸道和下呼吸道中减少。
 
附:英文原文

Title: Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Author: Lisa H. Tostanoski, Frank Wegmann, Amanda J. Martinot, Carolin Loos, Katherine McMahan, Noe B. Mercado, Jingyou Yu, Chi N. Chan, Stephen Bondoc, Carly E. Starke, Michael Nekorchuk, Kathleen Busman-Sahay, Cesar Piedra-Mora, Linda M. Wrijil, Sarah Ducat, Jerome Custers, Caroline Atyeo, Stephanie Fischinger, John S. Burke, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Esther A. Bondzie, Gabriel Dagotto, Makda S. Gebre, Catherine Jacob-Dolan, Zijin Lin, Shant H. Mahrokhian, Felix Nampanya, Ramya Nityanandam, Laurent Pessaint, Maciel Porto, Vaneesha Ali, Dalia Benetiene, Komlan Tevi, Hanne Andersen, Mark G. Lewis, Aaron G. Schmidt, Douglas A. Lauffenburger, Galit Alter, Jacob D. Estes, Hanneke Schuitemaker, Roland Zahn, Dan H. Barouch

Issue&Volume: 2020-09-03

Abstract: Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death1,2,3,4. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters5,6,7 and nonhuman primates8,9,10 have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates11,12,13. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.

DOI: 10.1038/s41591-020-1070-6

Source: https://www.nature.com/articles/s41591-020-1070-6

期刊信息

Nature Medicine:《自然—医学》,创刊于1995年。隶属于施普林格·自然出版集团,最新IF:30.641
官方网址:https://www.nature.com/nm/
投稿链接:https://mts-nmed.nature.com/cgi-bin/main.plex